TGFB2 and non-small cell lung carcinoma: Belagenpumatucel-L (Lucanix, NovaRx Corp.)was prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-β2 antisense transgene [128].